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Non-specific interstitial pneumonia in cigarette
smokers: a CT study
Abstract Thegoalofthisstudywasto
seek indirect evidence that smoking is
an aetiological factor in some patients
with non-specific interstitial pneumo-
nia (NSIP). Ten current and eight ex-
smokers with NSIP were compared to
controls including 137 current smokers
with no known interstitial lung disease
and 11 non-smokers with NSIP. Prev-
alence and extent of emphysema in 18
smokers with NSIP were compared
with subjects meeting GOLD criteria
for chronic obstructive pulmonary dis-
ease (COPD; group A; n=34) and
healthy smokers (normal FEV1;g r o u p
B; n=103), respectively. Emphysema
was present in 14/18 (77.8%) smokers
withNSIP.Emphysemadidnotdifferin
prevalence between NSIP patients and
group A controls (25/34, 73.5%), but
was strikingly more prevalent in NSIP
patients than in group B controls
(18/103, 17.5%, P<0.0005). On mul-
tiple logistic regression, the likelihood
of emphysema increased when NSIP
was present (OR=18.8; 95% CI=5.3–
66.3; P<0.0005) and with increasing
age (OR=1.04; 95% CI=0.99–1.11;
P=0.08).Emphysemaisasprevalentin
smokers with NSIP as in smokers with
COPD,andisstrikinglymoreprevalent
in these two groups than in healthy
smoking controls. The association be-
tween NSIP and emphysema provides
indirect support for a smoking patho-
genesis hypothesis in some NSIP
patients.
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Introduction
In recent years, cigarette smoking has been implicated in
the development of various interstitial lung diseases:
respiratory bronchiolitis-associated interstitial lung dis-
ease, desquamative interstitial pneumonia (DIP) and pul-
monary Langerhans cell histiocytosis are now considered
to represent different types of response to cigarette smoke
exposure [1, 2]. Cigarette smoking is believed to be a risk
factor for the development of idiopathic pulmonary
fibrosis, and in some individuals emphysema and pulmo-
nary fibrosis coexist [3, 4]. In a retrospective study of high-
resolution CT (HRCT) appearances in patients with
biopsy-proven DIP, two out of six smokers showed
HRCT features suggestive of fibrotic non-specific intersti-
tial pneumonia (NSIP) rather than DIP [5]. This has led to
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develop a pattern of fibrotic NSIP.
However, support for this hypothesis can come only
from indirect evidence, as it is not practicable to undertake
a prospective longitudinal evaluation of smokers and non-
smokers, necessarily lasting for many years, to determine
whether NSIP, a relatively rare disorder, develops selec-
tively in some smokers. Support for the idea of a smoking-
related pathogenesis for NSIP could be established from
two sources. First, an association between NSIP andknown
smoking-related damage, such as centrilobular emphyse-
ma, could suggest that NSIP and emphysema have
common pathogenetic features. Secondly, differences in
the HRCT appearances of NSIP itself in smokers and non-
smokers would support the hypothesis that smoking status
is linked to pathogenesis in a subset of patients. This
retrospective study was constructed to determine whether
such evidence exists.
The prevalence of pulmonary emphysema in NSIP was
compared to that in smoking control subjects enrolled in a
smoking cessation study undergoing limited HRCT exam-
ination and subdivided into subjects meeting pulmonary
function criteria for chronic obstructive pulmonary disease
(COPD) and those with normal FEV1.
Some of the results of these studies have been previously
reported in the form of an abstract [6].
Materials and methods
NSIP patients
Twenty-nine consecutive patients with fibrotic NSIP
(diagnosed on open or video-assisted thoracoscopic biopsy,
with all biopsies reviewed by the same two histopatholo-
gists) and concurrent HRCT (within 12 months, median
2 months) between January 1990 and June 2004 were
studied. There were 19 men and 10 women, median age
was 53 years, range 31–68 years (mean and SD given in
Table 1). The individuals were classified as current
smokers, ex-smokers (a minimum of one cigarette a day
for a minimum of 1 year, stopping at least 6 months before
presentation), or those who had never smoked (non-
smokers). Patients with an environmental exposure to a
fibrogenic agent or with a connective tissue disease were
not included in the study population.
Smoking control population
A cohort of 137 current smokers who had undergone a
limited HRCT of the lungs comprised the control group.
These subjects had been enrolled in a smoking cessation
study at our institution between May 2002 and June
2004. Approval was obtained from our institutional
ethics committee for the smoking cessation trial, and all
patients gave written informed consent after the purpose
and nature of the CT examination were explained.
Enrolment in the smoking cessation study required either
that patients met GOLD criteria for COPD [7] (group A,
n=34) or that FEV1 levels were normal, i.e. >90% of
predicted (group B, n=103).
Smoking controls were sub-categorised as “healthy”
smokers or as COPD controls. COPD controls (n=34)
fulfilled GOLD group II or III criteria, defined on
spirometry by a post-bronchodilator FEV1 of 30–80%
predicted following the inhalation of salbutamol (400 µg
via MDI) [7]. The pre-bronchodilator forced expiratory
ratio (FER) was <70%, and reversibility to bronchodilator
was less than 12% or 200 ml. Subjects in this group were
aged 40–80 years, current smokers of at least five
cigarettes per day with a greater than 10-pack-year
history and no history of atopy, asthma, or other
respiratory disease. Individuals with a history of malig-
nancy in the past 5 years, excepting basal-cell skin
carcinoma, were excluded. Use of inhaled corticosteroids,
theophylline, long-acting b agonists and non-steroidal
anti-inflammatory drugs was not permitted. Permitted
non-anti-inflammatory therapy included medication for
ischemic heart disease and hypertension.
“Healthy” smokers (group B, n=103) were defined on
spirometry by FEV1 >90% predicted and FER of >70%.
They were matched with the COPD subjects in terms of
age, sex, and smoking history. Exclusion criteria included a
history of atopy or any respiratory disease including
chronic simple bronchitis. Respiratory medication was not
permitted during the duration of the study. All smokers
were actively helped in efforts to stop smoking.
Pulmonary function tests
In all patients, pulmonary function tests, performed within
1 month of CT, included FEV1, FVC, and DLCO corrected
Table 1 Demographic data and pack-year smoking histories compared between NSIP patients and the smoking control groups
NSIP patients (current
and ex-smokers) (n=18)
Group A (meeting criteria
for COPD) (n=34)
Group B (FEV1 >90
% of predicted) (n=103)
Age (mean ± SD) 52.8±7.7a** 59.4±10.2a** 53.6±8.8
Male/female 13:5a* 17:17 42:56a*
Pack-year smoking history (median, range) 22.5a**, b**** (3–70) 60b**** (25–190) 44a** (10–195)
Entries in a row marked with the same letters are statistically different. *P=0.03, **P<0.01, ***P=0.001, ****P<0.0001
1680for haemoglobin concentration, expressed as percentages
of the predicted normal values.
High-resolution CT
Computed tomography was performed on a four-channel
multidetector Somatom Volume Zoom CT system (Sie-
mens, Erlangen, Germany) using 1.25-mm collimation and
a gantry rotation time of 0.8 ms, or on an electron beam CT
system (Imatron, San Francisco, CA) using 1.5-mm
collimation and an acquisition time of 100 ms. Lung
image datasets were reconstructed with a high spatial
frequency algorithm and viewed on work stations at
window settings appropriate for the lung parenchyma.
The asymptomatic smokers enrolled in the smoking
cessation trial had a limited high-resolution CT consisting
of four interspaced 1.25-mm sections: (1) at the mid aortic
arch, (2) at the main carina, (3) equally spaced between the
main carina and the dome of the higher hemi-diaphragm
and (4) 1 cm above the dome of the higher hemi-
diaphragm. Patients with NSIP had a high-resolution CT
of the entire lungs, with sections obtained at 10-mm
intervals in the supine position in full inspiration. From
these CT examinations, four sections corresponding to
those acquired in the asymptomatic smoking controls were
retrospectively selected and stored as a separate series.
All CT examinations were independently reviewed by
two experienced observers who were unaware of clinical
information or biopsy findings. All potential smoking-
related abnormalities were scored. The observers were
unaware of the study design and specifically that the
prevalence of emphysema was a primary focus of the study.
In NSIP patients and smoking controls, the presence or
absence of emphysema was recorded; disagreement was
resolved by consensus. Subsequently, in NSIP patients, the
five CT sections were scored to the nearest 5% for the
extent of lung with interstitial disease. An estimation was
made to the nearest 5% (summing to 100%) of the
contribution made by individual patterns as defined in the
Fleischner Society glossary [8] (ground-glass opacification
with traction bronchiectasis, pure ground-glass opacifica-
tion, honeycombing, a reticular pattern not otherwise
specified, nodules, lobules of decreased attenuation likely
to represent air-trapping, a pattern resembling the appear-
ance of pulmonary Langerhans cell histiocytosis, “crazy
paving” pattern and consolidation). The extents of
individual patterns (examples shown in Figs. 1, 2 and 3)
were derived, and the mean values for the two observers
were analysed.
Data analysis
Analyses were performed with STATA software (Stata data
analysis software; Computing Resource Center, Santa
Monica, CA). A P-value of <0.05 was taken to indicate
statistical significance. Interobserver variation was quanti-
fied using Kappa statistics or, for continuous variables, the
single determination standard deviation. Analyses were
undertaken to examine the following questions.
1) Does the prevalence of emphysema differ between
patients with NSIP and control smoking subjects in
group A (individuals meeting GOLD criteria for
COPD)? This question was evaluated using Fisher’s
exact test, and then using multiple logistic regression,
adjusting for age, gender and the pack-year smoking
history.
2) Does the prevalence of emphysema differ between
patients with NSIP and control smoking subjects in
group B (those with normal FEV1 levels)? This
question was examined (a) with the retention of both
ex- and current smokers with NSIP and (b) with the
exclusion of ex-smokers with NSIP (in order to
exclude bias due to a “healthy-smoker effect”). Sub-
group comparisons were made using Fisher’s exact
test, and then using multiple logistic regression to
adjust for age, gender and the pack-year smoking
history.
3) Does the presence or extent of HRCT features of
interstitial lung disease differ between non-smokers
with NSIP and ex/current smokers with NSIP? For
HRCT features occurring in a minority of patients,
prevalence was compared using Fisher’s exact test,
with further evaluation of significant trends using the
Kruskal-Wallis test (examining prevalence differences
across non-smokers, ex-smokers and current smokers).
For HRCT features present in the majority of patients,
the extent of patterns was compared between sub-
groups using Wilcoxon’s rank sum test.
Fig. 1 Thin-section CT of a 44-year-old female non-smoker with
NSIP showing widespread diffuse ground-glass opacification with
some thickening of the interlobular septa (crazy-paving pattern).
Total extent of interstitial disease was scored as 35% (40% assigned
as ground-glass opacification without traction bronchiectasis and
60% as crazy-paving pattern)
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Demographic details and pack-year smoking histories
As shown in the Table 1, NSIP smoking patients were
younger than group A controls and had a much lower pack-
year smoking history (median 22.5, range 3–70 versus
median 60, range 25–190, P<0.0001). NSIP patients had a
significantly lower pack-year smoking history and were
more likely to be male than group B controls. Review of
case records revealed that at presentation all NSIP patients
had a history of exertional dyspnea, and basal inspiratory
crackles at clinical examination. None had a prior diagnosis
of COPD. The median duration of symptoms was
24 months (range 4–120 months). Eight patients were ex-
smokers (median pack-years: 10, range: 5–30), and ten
patients were current smokers (median pack-years: 46,
range: 10–70).
Prevalence of emphysema in NSIP patients and group
A (smokers with COPD)
The prevalence of emphysema did not differ between NSIP
patients (14/18, 77.8%) and group A control subjects
(25/34, 73.5%), P=0.74. On logistic regression, there was
no significant or marginal difference in the prevalence of
emphysema between the two sub-groups after adjustment
for age, gender and pack-year smoking history.
Prevalence of emphysema in NSIP patients
and in group B (healthy smokers)
Emphysema was present in 14 out of 18 NSIP cases
(77.8%) compared to 18 of 103 group B control subjects
(17.5%), P<0.0005 (Fig. 1). On logistic regression, the
presence of emphysema was associated with a diagnosis of
NSIP [odds ratio 18.8; 95% confidence interval (95% CI)
5.3–66.2; P<0.0005] and with increasing age (odds ratio
1.04; 95% CI0.99–1.11; P=0.08). Gender and the pack-
year smoking history were not separately linked to the
presence of emphysema.
With the exclusion of 9 ex-smokers with NSIP, the
trends were unchanged. Emphysema (present in 9 of 10
current smokers with NSIP) was more prevalent than in
group B control subjects (18 of 103) (P<0.0005). On
Fig. 2a, b Thin-section CT of two current smokers with NSIP. a A
43-year-old woman with a 15-pack-year smoking history displaying
diffuse ground-glass opacification with superimposed centrilobular
emphysema. Total extent of interstitial disease was scored as 95%
(20% attributed to emphysema, and 80% to ground-glass opacifi-
cation without traction bronchiectasis). b A 60-year-old man with a
45-pack-year smoking history with diffuse ground-glass opacifica-
tion with traction bronchiectasis (extent scored as 100%)
Fig. 3 Thin-section CT of a current smoker with NSIP (60-year-old
woman with a 39-pack-year smoking history). Total extent of
interstitial disease was scored as 40% (50% attributed to a reticular
pattern, 30% to ground-glass opacification with traction bronchiec-
tasis, and 20% to ground-glass opacification without traction
bronchiectasis)
1682logistic regression, the presence of emphysema was again
associated with a diagnosis of NSIP (odds ratio 57.4; 95%
CI6.3–516.4; P<0.0005) and with increasing age (odds
ratio 1.06 per year of increase; 95% CI1.00–1.13; P=0.04).
Gender and the pack-year smoking history were not
separately linked to the presence of emphysema.
CT extent of emphysema compared
between sub-groups
Inter-observer agreement for the presence or absence of
emphysema on HRCT, combining NSIP and control
subjects, was excellent (κ=0.87). The single-determination
standard deviation for the extent of emphysema on CTwas
4.6%. The extent of emphysema on CT did not differ
between patients with NSIP (median 11.2%, range 0–
51.7%) and group A COPD control subjects (median 4.3%,
range 0–74.4%), P=0.39, and this finding was unchanged
(P=0.50) when patients with no emphysema were
excluded. Emphysema was more extensive in NSIP
patients than in group B healthy smoking control subjects
(median 0, range 0–18.5), P<0.0001. This finding
remained significant, P<0.005, when patients with no
emphysema were excluded.
CT interstitial patterns compared between smokers
and non-smokers with NSIP
The single-determination SDs for the CTextent of ground-
glass opacification with traction bronchiectasis, pure
ground-glass opacification, and a reticular pattern were
5.4, 10.7, and 13.4%, respectively. Agreement on the
presence or absence of a crazy-paving pattern was fair to
moderate (κ=0.39). Nodules, a pattern consistent with
Langerhans cell histiocytosis, significant honeycombing,
lobules of decreased attenuation or consolidation occurred
in fewer than five NSIP patients, and these patterns were
not analysed further.
The total extent of interstitial disease, the extent of
honeycombing, the extent of ground glass (with or without
traction bronchiectasis) and the extent of a reticular pattern
did not differ significantly between non-smokers and
current/ex-smokers. On logistic regression, the presence of
emphysema was not linked to the extent of any of these
HRCT patterns. A crazy-paving pattern was present in 7 of
10 non-smokers, 2 of 8 ex-smokers, but in none of 11
current smokers (P<0.01, chi-squared test for trend).
Functional significance of emphysema in smokers
and non-smokers with NSIP
The presence of emphysema on HRCTwas associated with
higher FVC levels (88.6±25.3 versus 69.4±20.6%, P=
0.03), despite slightly lower DLCO levels (42.8±12.8
versus 49.1±18.7%, P=0.30). On multivariate analysis,
FVC levels diminished significantly with increasingly
extensive interstitial lung disease [regression coefficient
(RC) = −0.96, 95% CI = −1.8 to −0.1, P=0.03] and
increased marginally when emphysema was present (RC=
15.5; 95% CI=−1.1 to 32.2; P=0.07). DLCO levels
diminished significantly with increasingly extensive inter-
stitial lung disease (RC=−0.69; 95% CI=−1.3 to −0.1; P=
0.02) and marginally with the presence of emphysema
(RC=−8.9; 95% CI=−20.6 to 2.8; P=0.13). The FVC-to-
DLCO ratio was higher in patients with emphysema
(median 1.99, range 1.35–4.14) than in those without
emphysema (median 1.43, range 1.15–3.46), P<0.01.
Discussion
We found a higher than expected prevalence of emphysema
in cigarette smokers with NSIP, and our results support the
concept that smoking may contribute to the pathogenesis of
NSIP in some individuals.
The causative role of smoking in pulmonary fibrosis
remains controversial. Specifically, relationships between
cigarette smoking and the two commonest fibrosing
idiopathic interstitial pneumonias, UIP and NSIP, have
not been fully elucidated. Clinical studies that have sought
to identify the relative risk of developing fibrosis in
cigarette smokers are difficult to interpret, largely due to
differences in the definition of the presence and type of
interstitial fibrosis. Indeed, studies of subjects with idio-
pathic pulmonary fibrosis (IPF) have reported a varying
prevalence of current or previous smokers (41–83%) [9–
16]. However, these studies predate the reclassification of
IPF that clearly distinguishes between UIP and NSIP [17].
Possible pathogenetic mechanisms linking smoking with
interstitial fibrosis include excessive oxidative stress [18,
19] and the modulation of oxidative stress by the up-
regulation of protease inhibitors (such as tissue inhibitor of
metalloproteinases) [20] or a direct effect of smoking on
the extracellular thiol/disulfide redox environment [21]. In
IPF, it has recently been reported that severity-adjusted
mortality is higher in current and former smokers than in
life-long non-smokers, suggesting that smoking status is
linked to the rapidity of progression of pulmonary fibrosis
[22]. This effect may not be disease specific. A study by
Craig et al. suggested that cigarette smokers may develop a
pattern of fibrotic NSIP, either as a primary disorder or
evolving from pre-existing DIP [5]. In this context, it is
conceivable that in a subset of patients with a smoking
history, macrophage accumulation of DIP recedes as time
passes, leaving residual interstitial fibrosis in the form of
NSIP.
Further indirect support for the hypothesis of a cigarette
smoking-related pathogenesis in NSIP comes from the
observation that HRCT morphologic features differ
1683between non-smokers and current or former smokers. A
crazy-paving pattern (the appearance of thickened inter-
lobular septa superimposed on areas of ground-glass
opacification) was frequent in non-smokers but wasseldom
present in ex- or current smokers and was never seen when
significant smoking-related macrophage accumulation was
present at biopsy. Crazy-paving was first described in
alveolar proteinosis [23] and is now regarded as a non-
specific feature present in a variety of infectious, neoplastic
and inhalational disorders [24]. Despite the statistical
significance and novelty of the crazy-paving association,
the low number of NSIP patients in the smoking sub-
groups demands that this observation be interpreted with
caution. However, the finding of differences in HRCT
patterns between smokers and non-smokers with NSIP
indirectly supports the concept of smoking-related NSIP.
Two alternative explanations for the association between
emphysema and NSIP merit consideration. A common
genetic predilection might exist, but such a predilection is
likely to relate to a pathogenetic mechanism that is
common to the two diseases. Whether the linking trigger
is genetic, environmental or a combination, our findings
can be interpreted as justification for an increased focus on
the candidate shared mechanisms discussed above.
Furthermore, it is difficult to argue that the high prevalence
of emphysema in NSIP in our study resulted from the
disclosure of trivial emphysema by the presence of
interstitial lung disease. Firstly, there was smoking-related
centrilobular emphysema in all cases in lung regions not
affected by NSIP (although there was also an admixture of
the two processes in most patients). Secondly, the presence
of emphysema across the whole NSIP cohort was
associated with a clear effect on the FVC-to-DLCO ratio,
indicative of overtly functionally significant disease.
The selection of control subjects is an important further
consideration in a study of this type. Firstly, the CT
examinations analysed were performed in consecutive
attendees at a smoking cessation clinic and this may have
introduced bias. However, a “healthy-smoker effect” [25]
should mean that attendance at a smoking cessation clinic
is associated with a greater likelihood of significant
underlying lung damage; this would be consistent with
the high prevalence of emphysema seen on HRCT in the
control cohort. Thus, it appears highly unlikely that
findings are spuriously positive because of an under-
statement of the prevalence of emphysema in smokers.
More importantly, it was necessary to ensure that smoking
controls and NSIP patients were comparable in having no
prior diagnosis of smoking-related COPD. However, it
could be argued that COPD might have become evident in
some of the NSIP patients but for the development of
pulmonary fibrosis lung disease, and this prompted us to
re-evaluate associations in a combined analysis of NSIP
patients and patients meeting GOLD criteria for a diagnosis
of COPD. Strikingly, the prevalence of emphysema in
these two groups was very similar.
A potentially important limitation in study design was
that the HRCT scorers could not be blinded as to patient
sub-group in determining the prevalence of emphysema
due to the obvious presence of NSIP. To overcome this
constraint, the primary purpose of the study (examining
associations between NSIP and the presence of emphyse-
ma) was not divulged to the scorers prior to the scoring of
NSIP cases (which preceded the scoring of smoking
controls). The high prevalence of emphysema in the
smoking controls indicates that systematic underestimation
of the presence of emphysema because of awareness of
study design was unlikely.
The small number of NSIP patients in our study needs to
be emphasised. NSIP is an uncommon disease, especially
with the exclusion of patients with a primary cause and
those with clinico-radiological features overlapping with
those of hypersensitivity pneumonitis or organizing pneu-
monia. The NSIP subset examined in the present study
consisted of patients presenting with the clinical features of
IPF, as studied previously in the U.K. [26] and the U.S.A.
[27]. Nevertheless, our observations can now be tested in
other cohorts of similar size.
In conclusion, the association of pulmonary emphysema
with NSIP (and, to a lesser extent, observations relating to a
crazy-paving pattern) provide support for cigarette smok-
ing as a pathogenetic factor in a subset of NSIP patients.
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